Goodwin.Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clinical and Applied Thrombosis/Hematosis1996;2(Suppl. 1):28-34.
2.
Zacharski LR , Costantini V.Blood coagulation activation in cancer: challenges for cancer treatment. Hämostaseologie1995 ;15:14.
3.
Clarke-Pearson DL, Coleman RE, Synan IS, et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin . Am J Obstet Gynecol1983;145:606.
4.
Heilmann L., von Tempelhoff G-F, Herrle B., et al. A prospective randomized trial of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) in patients with gynecologic cancer . Thromb Haemost1995;73 (Suppl. 1):974.
5.
von Tempelhoff G-F, Dietrich M., Schneider D., Wolf H., Heilmann L.A prospective randomized study on the perioperative treatment with either low molecular weight heparin or unfractionated standard heparin for thrombosis prophylaxis in patients with gynecologic malignancy . Ann Hematol1996;(Suppl. 1)72:209.
6.
Kakkar VV, Murray Wjg.Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a cooperative study. Br J Surg1985;72:786.
